One-Year Comparative Effectiveness of Upadacitinib vs Tofacitinib for Ulcerative Colitis: A Multicenter Cohort Study

被引：8
|
作者：
Dalal, Rahul S. [1 ]
Kallumkal, Govind [2 ]
Cabral, Heidy J. [1 ]
Barnes, Edward L. [3 ]
Allegretti, Jessica R. [1 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Gastroenterol Hepatol & Endoscopy, Boston, MA 02115 USA
[2] Univ N Carolina, Dept Med, Chapel Hill, NC USA
[3] Univ N Carolina, Dept Med, Div Gastroenterol, Chapel Hill, NC USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 08期
关键词：
small molecule; Janus kinase inhibitor; inflammatory bowel disease; remission; biologic; MAINTENANCE THERAPY; INDUCTION;
D O I：
10.14309/ajg.0000000000002746
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
INTRODUCTION: The comparative effectiveness of upadacitinib and tofacitinib for ulcerative colitis (UC) is poorly understood. METHODS: In this retrospective cohort study, we compared steroid-free clinical remission (SFCR) and endoscopic response/remission at 52 weeks among adults initiating upadacitinib or tofacitinib for UC. RESULTS: A total of 155 patients initiated upadacitinib (n = 81; 30% prior tofacitinib exposure) or tofacitinib (n = 74; 0% prior upadacitinib exposure). After inverse probability of treatment-weighted logistic regression, upadacitinib was associated with significantly higher odds of SFCR (odds ratio 3.01, 95% confidence interval 1.39-6.55) vs tofacitinib. There were no differences for endoscopic response/remission. DISCUSSION: Upadacitinib was more effective at achieving SFCR in UC at 52 weeks vs tofacitinib.
引用
收藏
页码：1628 / 1631
页数：4
相关论文
共 50 条
  • [31] Longer-term tofacitinib effectiveness for the treatment of ulcerative colitis: Two-year outcomes from a UK observational cohort study
    Honap, S.
    Sharma, E.
    Ray, S.
    Mawdsley, J.
    Anderson, S.
    Samaan, M.
    Pavlidis, P.
    Irving, P.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I414 - I415
  • [32] LONGER-TERM TOFACITINIB EFFECTIVENESS FOR THE TREATMENT OF ULCERATIVE COLITIS: TWO-YEAR OUTCOMES FROM A UK OBSERVATIONAL COHORT STUDY
    Honap, Sailish
    Sharma, Esha
    Ray, Shuyra
    Mawdsley, Joel
    Anderson, Simon H.
    Samaan, Mark A.
    Pavlidis, Polychronis
    Irving, Peter M.
    GASTROENTEROLOGY, 2022, 162 (07) : S988 - S989
  • [33] Longer-term tofacitinib effectiveness for the treatment of ulcerative colitis: Two-year outcomes from a UK observational cohort study
    Honap, S.
    Sharma, E.
    Ray, S.
    Mawdsley, J.
    Anderson, S.
    Samaan, M.
    Pavlidis, P.
    Irving, P.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I414 - I415
  • [34] One-year outcomes in sepsis: a prospective multicenter cohort study in Japan
    Keibun Liu
    Shinichi Watanabe
    Kensuke Nakamura
    Hidehiko Nakano
    Maiko Motoki
    Hiroshi Kamijo
    Matsuoka Ayaka
    Kenzo Ishii
    Yasunari Morita
    Takashi Hongo
    Nobutake Shimojo
    Yukiko Tanaka
    Manabu Hanazawa
    Tomohiro Hamagami
    Kenji Oike
    Daisuke Kasugai
    Yutaka Sakuda
    Yuhei Irie
    Masakazu Nitta
    Kazuki Akieda
    Daigo Shimakura
    Hajime Katsukawa
    Toru Kotani
    David McWilliams
    Peter Nydahl
    Stefan J. Schaller
    Takayuki Ogura
    Journal of Intensive Care, 13 (1)
  • [35] One year endoscopic and histologic outcomes to tofacitinib therapy in refractory ulcerative colitis
    Verstockt, B.
    Aden, K.
    Alsoud, D.
    Outtier, A.
    Sabino, J.
    Rosenstiel, P.
    Vermeire, S.
    De Hertogh, G.
    Schreiber, S.
    Ferrante, M.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S456 - S457
  • [36] ONE YEAR ENDOSCOPIC AND HISTOLOGIC OUTCOMES TO TOFACITINIB THERAPY IN REFRACTORY ULCERATIVE COLITIS
    Verstockt, Bram
    Alsoud, Dahham
    Outtier, An
    Sabino, Joao
    Vermeire, Severine
    De Hertogh, Gert
    Ferrante, Marc
    GASTROENTEROLOGY, 2021, 160 (06) : S702 - S702
  • [37] Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry
    Straatmijer, Tessa
    van Schaik, Fiona D. M.
    Bodelier, Alexander G. L.
    Visschedijk, Marijn
    de Vries, Annemarie C.
    Ponsioen, Cyriel Y.
    Pierik, Marieke
    van Bodegraven, Ad A.
    West, Rachel L.
    de Boer, Nanne K. H.
    Srivastava, Nidhi
    Romkens, Tessa E. H.
    Hoekstra, Jildou
    Oldenburg, Bas
    Dijkstra, Gerard
    van der Woude, Janneke C.
    Lowenberg, Mark
    Mujagic, Zlatan
    Biemans, Vince B. C.
    Van der Meulen-de Jong, Andrea E.
    Duijvestein, Marjolijn
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (01) : 117 - 126
  • [38] Comparative Effectiveness and Safety of Upadacitinib and Vedolizumab in Anti-TNF Experienced Patients with Ulcerative Colitis: A Retrospective Study
    Sror, N.
    Leibovitzh, H.
    Hirsch, A.
    Thurm, T.
    Ron, Y.
    Maharshak, N.
    Cohen, N. A.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1573 - i1574
  • [39] Comparative efficacy and safety of upadacitinib vs tofacitinib as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison
    An, Y-K
    Reinisch, W.
    Tran, J.
    Patel, K.
    Borruel, N.
    Melmed, Gy
    Wegrzyn, L.
    Levy, G.
    Ilo, D.
    Gonzalez, Y. Sanchez
    Panaccione, R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 128 - 129
  • [40] Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study
    Perin, Ramir Luan
    Magro, Daniela Oliveira
    Andrade, Adriana Ribas
    Argollo, Marjorie
    Carvalho, Nayara Salgado
    Damiao, Aderson Omar Moura Cintra
    Dotti, Adriana Zanoni
    Ferreira, Sandro da Costa
    Flores, Cristina
    Ludvig, Juliano Coelho
    Nones, Rodrigo Bremer
    Queiroz, Natalia Sousa Freitas
    Parra, Rogerio Serafim
    Steinwurz, Flavio
    Teixeira, Fabio Vieira
    Kotze, Paulo Gustavo
    CROHNS & COLITIS 360, 2023, 5 (01)
12345